RNXT on Nasdaq

RenovoRx, Inc.

American surgical and medical instruments and apparatus company. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with PetVivo Holdings, Inc., SeaStar Medical Holding Corp or Sintx Technologies, Inc., or pick any stock.

  • TickerRNXT on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersMountain View, California1
  • Incorporated inDE2
  • Business address2570 W. El Camino Real, Ste. 320,, Mountain View, Ca 940402
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

70.9%Gross margin3
-1114.0%Operating margin3
-994.5%Net margin3
2511.6%Revenue growth, 20253
-206.0%Return on equity3
-$11.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue2¢$327.0K
  • Research and development46¢$6.3M
  • Selling, general and admin52¢$7.0M
  • Income tax0¢$2.0K

Out of $1.1M in revenue.3 The company lost money this year.

Financial statements

Revenue3$1.1M in 2025+2512% since 2024
0$500.0K$1.0M$1.5M2024: $43.0K$43.0K20242025: $1.1M$1.1M2025+2512%
Gross profit3$796.0K in 2025+1751% since 2024
0$200.0K$400.0K$600.0K$800.0K2024: $43.0K$43.0K20242025: $796.0K$796.0K2025+1751%
Operating income45673-$12.5M in 2025+290% since 2020
-$15.0M-$10.0M-$5.0M02020: -$3.2M-$3.2M20202021: -$5.7M-$5.7M2021+77%2022: -$9.9M-$9.9M2022+75%2023: -$11.4M-$11.4M2023+15%2024: -$11.0M-$11.0M2024−4%2025: -$12.5M-$12.5M2025+14%
Net income45673-$11.2M in 2025+194% since 2020
-$15.0M-$10.0M-$5.0M02020: -$3.8M-$3.8M20202021: -$6.3M-$6.3M2021+67%2022: -$9.9M-$9.9M2022+56%2023: -$10.2M-$10.2M2023+3%2024: -$8.8M-$8.8M2024−14%2025: -$11.2M-$11.2M2025+27%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Revenue$1.1M$43.0K
Cost of Revenue$327.0K$0
Gross profit$796.0K$43.0K
Research and development$6.3M$6.0M
Selling, general and administrative$7.0M$5.0M
Total operating expenses$13.3M$11.0M
Loss from operations-$12.5M-$11.0M
Change in fair value of warrant liability$915.0K$1.8M
Interest income, net$427.0K$384.0K
Total other income, net$1.3M$2.2M
Net loss-$11.2M-$8.8M
Net loss per share - basic-$0.32-$0.40
Net loss per share - diluted-$0.32-$0.40
Weighted average shares of common stock - basic35.3M shares22.3M shares
Weighted average shares of common stock - diluted35.3M shares22.3M shares

Compare RenovoRx, Inc. with another company

Leadership

Who has led RenovoRx, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Shaun Bagai2021–now

Chief financial officer

  1. Paul Manners2021
  2. Christopher John Lehman2021
  3. James M. Ahlers2022
  4. Mark Voll2026–now

Chief operating officer

  1. Angela Nelms2022–2024
2025
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerLeesa R. Gentry named Apr 22, 2024 to Apr 9, 202622

Timeline

  1. Aug 25, 2021New chief executive Shaun Bagai becomes CEO10

Filings

249 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 55 major events, 102 insider forms, 12 large holders, 3 private raises, 56 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 2, 20264 EDGAR
  3. Oct 2, 20264 EDGAR
  4. Oct 2, 20264 EDGAR
  5. Sep 15, 20264 EDGAR
  6. Aug 20, 20268-K EDGAR
  7. Aug 13, 202610-Q EDGAR
  8. Aug 13, 20268-K/A EDGAR
  9. Aug 12, 20268-K EDGAR
  10. Aug 4, 20268-K EDGAR
  11. Jul 2, 20268-K EDGAR
  12. Jun 30, 2026S-8 EDGAR
  13. Jun 30, 20268-K EDGAR
  14. Jun 24, 20264 EDGAR
  15. May 21, 20264 EDGAR
  16. May 15, 202610-K/A EDGAR
  17. May 14, 202610-Q EDGAR
  18. May 14, 20268-K EDGAR
  19. Apr 30, 2026DEF 14A EDGAR
  20. Apr 27, 2026EFFECT EDGAR

The 249 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

35 open-market trades by officers, directors and large owners since October 2021: 35 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 19, 2026VOLL MARKChief Financial OfficerBuy25,000$0.79$19.8KForm 4
Mar 20, 2026Marton LaurenceDirectorBuy9,720Form 4
Mar 20, 2026Bagai ShaunChief Executive OfficerBuy24,300Form 4
Mar 20, 2026VOLL MARKChief Financial OfficerBuy97,200Form 4
Jan 21, 2026Agah RamtinChief Medical OfficerBuy10,000$1.00$10.0KForm 4
Dec 31, 2025Agah RamtinChief Medical OfficerBuy9,795$0.86$8.4KForm 4
Dec 30, 2025Agah RamtinChief Medical OfficerBuy205$0.83$170Form 4
Dec 18, 2025Bagai ShaunChief Executive OfficerBuy5,000$0.90$4.5KForm 4
Dec 17, 2025Bagai ShaunChief Executive OfficerBuy5,000$0.85$4.2KForm 4
Dec 16, 2025Agah RamtinChief Medical OfficerBuy12,000$0.85$10.2KForm 4
Dec 5, 2025Agah RamtinChief Medical OfficerBuy10,000$0.96$9.6KForm 4
Nov 24, 2025Agah RamtinChief Medical OfficerBuy12,000$0.80$9.6KForm 4
Nov 21, 2025Agah RamtinChief Medical OfficerBuy10,000$0.80$8.0KForm 4
Aug 25, 2025Bagai ShaunChief Executive OfficerBuy5,000$0.91$4.5KForm 4
Aug 22, 2025Bagai ShaunChief Executive OfficerBuy5,000$0.95$4.8KForm 4
Jun 5, 2025Agah RamtinChief Medical OfficerBuy21,000$1.40$29.4KForm 4
Apr 15, 2025Agah RamtinChief Medical OfficerBuy15,000$0.90$13.5KForm 4
Apr 15, 2025Bagai ShaunChief Executive OfficerBuy7,500$0.91$6.8KForm 4
Apr 11, 2025Agah RamtinChief Medical OfficerBuy20,000$0.80$16.0KForm 4
Apr 10, 2025Kocak RonVP, Controller and PAOBuy6,500$0.79$5.1KForm 4

All 35 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 20, 2026Raised $10 million in a private offering of equity Form D: $10 million offered in all Form D
  2. Apr 11, 2024Raised $11.1 million in a private offering of equity Form D: $15 million offered in all Form D
  3. Jan 26, 2024Raised $6.1 million in a private offering of equity Form D: $15 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 28. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
AIGH Capital Management LLC4,405,439$4.3M0.4%+699,242
Bleichroeder LP1,666,098$1.6M0.3%No change
Vanguard Capital Management LLC1,443,742$1.4M0.0%−3,435
Geode Capital Management, LLC424,148$415.7K0.0%+42,425
Wealthspire Advisors, LLC252,525$247.5K0.0%No change
Vanguard Fiduciary Trust Co240,330$235.5K0.0%+82,428
Citadel Advisors LLC133,597$130.9K0.0%−99,087
Northern Trust Corp85,207$83.5K0.0%+43,046
Chicago Partners Investment Group LLC92,356$78.9K0.0%No change
Northwestern Mutual Wealth Management Co74,596$73.1K0.0%−24,864
Caprock Group, LLC63,940$62.7K0.0%No change
Jane Street Group, LLC46,399$45.5K0.0%+22,262
Kestra Advisory Services, LLC35,520$34.8K0.0%No change
Two Sigma Securities, LLC34,788$34.1K0.0%+16,892
XTX Topco Ltd29,983$29.4K0.0%−528
Clear Creek Financial Management, LLC29,058$28.5K0.0%New
State Street Corp26,152$25.6K0.0%No change
UBS Group AG20,820$20.4K0.0%+17,482
HighTower Advisors, LLC20,000$19.6K0.0%No change
Cetera Investment Advisers19,000$18.6K0.0%+1,000
Affinity Capital Advisors, LLC13,279$12.6K0.0%No change
Captrust Financial Advisors12,307$12.1K0.0%No change
Renaissance Technologies LLC11,400$11.2K0.0%−1,600
Morgan Stanley7,102$7.0K0.0%No change
Midway Capital Research & Management6,300$6.2K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27